Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBT (2020 - 2025)

Tarsus Pharmaceuticals has reported EBT over the past 6 years, most recently at -$6.2 million for Q4 2025.

  • Quarterly results put EBT at -$6.2 million for Q4 2025, up 72.97% from a year ago — trailing twelve months through Dec 2025 was -$64.2 million (up 43.43% YoY), and the annual figure for FY2025 was -$64.4 million, up 44.3%.
  • EBT for Q4 2025 was -$6.2 million at Tarsus Pharmaceuticals, up from -$12.7 million in the prior quarter.
  • Over the last five years, EBT for TARS hit a ceiling of $10.7 million in Q1 2021 and a floor of -$42.5 million in Q4 2023.
  • Median EBT over the past 5 years was -$21.3 million (2022), compared with a mean of -$19.4 million.
  • Biggest five-year swings in EBT: soared 647.93% in 2021 and later crashed 474.12% in 2023.
  • Tarsus Pharmaceuticals' EBT stood at -$14.4 million in 2021, then rose by 5.61% to -$13.6 million in 2022, then crashed by 211.62% to -$42.5 million in 2023, then soared by 45.63% to -$23.1 million in 2024, then soared by 72.97% to -$6.2 million in 2025.
  • The last three reported values for EBT were -$6.2 million (Q4 2025), -$12.7 million (Q3 2025), and -$20.2 million (Q2 2025) per Business Quant data.